STAT3 silencing by an aptamer-based strategy hampers the crosstalk between NSCLC cells and cancer-associated fibroblasts
The identification of new effective therapeutic options for non-small-cell lung cancer (NSCLC) represents a crucial challenge in oncology. Recent studies indicate that cancer-associated fibroblasts (CAFs) participate in tumor progression by establishing a favorable microenvironment that promotes can...
Saved in:
Main Authors: | Maria L. Ibba (Author), Giuseppe Ciccone (Author), Deborah Rotoli (Author), Gabriele Coppola (Author), Alfonso Fiorelli (Author), Silvia Catuogno (Author), Carla L. Esposito (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2023-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
STAT3 Gene Silencing by Aptamer-siRNA Chimera as Selective Therapeutic for Glioblastoma
by: Carla Lucia Esposito, et al.
Published: (2018) -
Aptamer-Mediated Targeted Delivery of Therapeutics: An Update
by: Silvia Catuogno, et al.
Published: (2016) -
Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL
by: Margherita Iaboni, et al.
Published: (2016) -
Identification of a novel RNA aptamer that selectively targets breast cancer exosomes
by: Carla Lucia Esposito, et al.
Published: (2021) -
Coupling Aptamers to Short Interfering RNAs as Therapeutics
by: Vittorio de Franciscis, et al.
Published: (2011)